Market Opportunity
Minimum Total Addressable Market across all solid tumors
Applicable to All Solid Tumors
BrachyClip addresses a massive unmet need across multiple cancer types
Cancer resections annually in the U.S.
Open, robotic, and laparoscopic procedures
Positive surgical resection & close margins
(<2mm distance)
Local tumor recurrences annually
35% of cancer mortality
Critical Impact: Average cost of local tumor recurrence is $100,000 per patient - representing a significant burden on both patients and the healthcare system.
Market Breakdown by Tumor Type
| Procedure | Annual Procedures | Market Potential |
|---|---|---|
| Breast | 282,000 | $1.3B |
| Liver | 282,000 | $1.3B |
| Prostate | 249,000 | $1.2B |
| Lung | 236,000 | $1.1B |
| Colorectal | 150,000 | $710M |
| Esophagogastric | 46,000 | $218M |
| Kidney | 76,000 | $360M |
| Pancreas | 60,000 | $284M |
| GYN | 60,000 | $284M |
| TOTAL | 1,445,000 | ≅ $6.8B |
A Win-Win-Win for Everyone
Hospital Benefit
Global Medicare Reimbursement: $4,735 per procedure
Facility Margin: $735
Commercial insurers reimburse 1.4-2.0× Medicare rates
Physician Benefit
Separate Professional Fee: $417 to Implant Seeds
MD Margin: $735
Additional revenue stream for surgical practices
BrachyClip Benefit
ASP: $4,000 per procedure
Gross Margin: $3,200
80% Gross Margin
Cost of Goods: $800 per procedure
Significant Commercial Potential
A large and growing market with favorable reimbursement landscape
Approximate U.S. Cases Per Year
Cancer resections (open/robotic/laparoscopic) within the chest, abdomen, pelvis and extremities
Minimally invasive procedures within the chest, abdomen, pelvis and extremities
Critical Challenge
Positive surgical resection and close (<2mm)
Local tumor recurrence*
Average cost: $100,000 per patient
* Accounts for 35% of cancer mortality
Current Landscape
IPSB, Though Highly Effective, Is Underutilized
Existing methods face significant limitations that restrict adoption and effectiveness
Current IPSB Strategies
"Free Hand" Seeds
Manual placement of individual radioactive seeds during surgery
Seed-Embedded Mesh
Radioactive seeds pre-loaded into surgical mesh
Seed-Embedded Sutures
Radioactive seeds integrated into surgical suture material
Critical Limitations of Current Methods
Not Adaptable to MIS
None of the current methods are suitable for minimally invasive surgical techniques which now dominate the type of surgical procedures.
Unpredictable Dose Distribution
All methods result in inconsistent radiation dose delivery to the target area, as locations are not fixed and seeds can migrate
High Personnel Exposure
Methods result in increased radiation exposure to operating room personnel
BrachyClip Addresses These Challenges
Our innovative clip-based delivery system provides predictable dosimetry ensuring fixed location, enables minimally invasive application, and reduces radiation exposure to surgical personnel
Strategic Partnership with Theragenics
Our partnership with Theragenics will be instrumental in scaling BrachyClip's reach, leveraging their extensive network of:
Hospitals in Network
Sales Professionals